v3.26.1
Acquisition, In-Licensing Arrangement and Sale of Investment - Acquisitions Narrative (Details)
$ / shares in Units, $ in Millions
Nov. 13, 2025
USD ($)
payment
$ / shares
Mar. 29, 2026
USD ($)
Dec. 31, 2025
USD ($)
Business Combination [Line Items]      
Goodwill   $ 71,409 $ 71,264
Metsera [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 65.60    
Payments to acquire business, gross $ 8,000    
Acquisitions of businesses, net of cash acquired $ 7,800    
Number of milestone payments | payment 3    
Noncash contingent value right $ 632    
Stock awards related to pre-acquisition services 475    
Identifiable intangible asset, net 8,000    
Goodwill 2,000    
Net deferred tax liabilities 1,600    
Contingent consideration liabilities $ 672    
Metsera [Member] | Total Payments to Former Metsera Shareholders [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 20.65    
Contingent value right $ 2,300    
Metsera [Member] | Phase 3 Clinical Trial [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 4.60    
Metsera [Member] | FDA Approval of MET-097i [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares 6.40    
Metsera [Member] | FDA Approval of MET-097i + MET-233i [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 9.65